Basic Information
Yttriga
Regulatory Information
EMEA/H/C/000596
Authorised
January 19, 2006
September 15, 2005
10
January 29, 2021
Company Information
Germany
Robert-Rossle-Str. 10 D-13125 Berlin
Eckert & Ziegler Radiopharma GmbH
Active Substances Detail
yttrium (90Y) chloride
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication To be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide. Radiopharmaceutical precursor - Not intended for direct use in patients.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Yttriga. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Yttriga.